Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by New York Medical College
Children's Research Institute
Baylor College of Medicine
M.D. Anderson Cancer Center
City of Hope Medical Center
Johns Hopkins University
Ohio State University
University of Utah
University of Michigan
Information provided by (Responsible Party):
Mitchell Cairo, New York Medical College Identifier:
First received: June 26, 2012
Last updated: October 4, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)